Answers are grounded in this paper and cite their sources.
Gestational diabetes mellitus (GDM) is associated with increased rates of fetal morbidity and mortality, both during the pregnancy and in the postnatal life. Current treatment of GDM includes diet with or without medications, but this management is expensive and poorly cost-effective for the health care systems. Strategies to prevent such condition would be preferable with respect to its treatment. The aim of this literature review was to evaluate studies reporting the efficacy of the most used approaches to prevent GDM as well as evidences of efficacy and safety of dietary supplementations. Systematic literature searches were performed in electronic databases, covering the period January 1983 to April 2014. Randomized controlled clinical trials were included. Quality of the articles was evaluated with the Jadad scale. We did not evaluate those articles that were already entered in the most recent systematic reviews, and we completed the research with the trials published thereafter. Of 55 articles identified, 15 randomized controlled trials were eligible. Quality and heterogeneity of the studies cannot allow firm conclusions. Anyway, trials in which only intake or expenditure has been targeted mostly reported negative results. On the contrary, combined lifestyle programs including diet control (orienting food intake, restricting energy intake) associated with moderate but continuous physical activity exhibit better efficacy in reducing GDM prevalence. The results from dietary supplements with myo-inositol or probiotics are promising. The actual evidences provide enough arguments for implementing large-scale, high-quality randomized controlled trials looking at the possible benefits of these new approaches for preventing GDM. Target Audience Obstetricians and gynecologists, family physicians Learning Objectives After completing this CME activity, physicians should be better able to summarize the benefits of myo-inositol during pregnancy because it is a safe insulin sensitizer substance able to improve glucose homeostasis and insulin sensitivity, also during pregnancy; therefore, it seems reasonable to implement its assumption starting, if possible, in the preconceptional period (ie, in women with polycystic ovary syndrome); to take into account the possibility of supplying probiotics for preventing GDM in women at risk for GDM development; as well as to encourage preconceptional weight loss in obese women focused to decrease weight-related infertility and pregnancy complications.
No takes yet. Share an insight, caveat, or question.
Facchinetti et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: